Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive DataBenzinga • 01/28/25
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)GlobeNewsWire • 01/27/25
Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/13/25
Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in IsraelGlobeNewsWire • 01/13/25
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United StatesGlobeNewsWire • 01/10/25
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025The Motley Fool • 12/24/24
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025GlobeNewsWire • 12/20/24
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related DiseasesBenzinga • 12/18/24
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?Zacks Investment Research • 12/18/24
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn'sInvestopedia • 12/17/24
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied DrugInvestors Business Daily • 12/17/24
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's DiseaseGlobeNewsWire • 12/17/24